Trump Links Paracetamol to Autism
Analysis based on 7 articles · First reported Sep 22, 2025 · Last updated Sep 22, 2025
The controversial claims by Donald Trump and Robert F. Kennedy Jr. linking Paracetamol to Autism could negatively impact the pharmaceutical industry, particularly companies producing Paracetamol, due to potential public fear and reduced sales. Conversely, companies involved in developing treatments for Autism, such as those focusing on vitamin folate, might see increased attention and investment.
Donald Trump's administration, led by Robert F. Kennedy Jr., is expected to announce a controversial claim linking the use of Paracetamol (Tylenol) during pregnancy to Autism. This assertion has been widely condemned by medical experts and organizations in the United Kingdom, including the United Kingdom — National Health Service, Durham University, University College London, and the KC Pharmaceuticals, who cite robust studies, including a 2024 Swedish study of 2.4 million births, that refute any causal link. Experts warn that this 'fearmongering' could stigmatize families with autistic children and prevent pregnant women from accessing safe pain relief. While a study from Harvard T.H. Chan School of Public Health and Mount Sinai suggested a potential link, they recommended judicious use rather than broad limitation. The administration's report is also expected to recommend a specific type of vitamin folate as a treatment for Autism.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard